REGENXBIO

All categories, Deals and Financing

Sarepta and REGENXBIO Settle AAV Patent Case

REGENXBIO disclosed a 23 September settlement with Sarepta, the University of Pennsylvania and Catalent resolving litigation over two patents involving manufacture and sale of Elevidys. Sarepta will pay REGENXBIO $39 million within ten days…

admin
September 23, 2026

Clinical Trial, Therapeutic Indication

FDA Places REGENXBIO’s RGX-121 on Clinical Hold After Spine MRI Findings

FDA placed the RGX-121 program on clinical hold after asymptomatic spinal MRI findings were identified in five CAMPSIITE participants treated approximately three to six years earlier. REGENXBIO no longer expects to resubmit the RGX-121…

admin
August 25, 2026

Sarepta and REGENXBIO Settle AAV Patent Case

FDA Places REGENXBIO’s RGX-121 on Clinical Hold After Spine MRI Findings

Saturday Rounds